Analysis of the fragile histidine triad (FHIT) gene in lobular breast cancer

European Journal of Cancer

Volumn 36, Issue 12, 2000, Pages 1552-1557

  Huiping, C ^a   Jonasson, J G ^a   Agnarsson, B A ^a   Sigbjornsdottir, B I ^a   Huebner, K ^b   Ingvarsson, S ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

FHIT; Fhit expression; Lobular breast cancer; LOH

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; GENE DELETION; GENE EXPRESSION; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

ACID ANHYDRIDE HYDROLASES; BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; GENE DELETION; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; NEOPLASM PROTEINS; PROTEINS; TRANSCRIPTION FACTORS;

EID: 0033854658     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00143-X     Document Type: Article

References (23)

1. Ohta M., Inoue H., Cotticelli M.G.et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 84:1996;587-597.
2. Croce C.M., Sozzi G., Huebner K. Role of FHIT in human cancer. J. Clin. Oncol. 17:1999;1618-1624.
3. Negrini M., Monaco C., Vorechovsky I.et al. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res. 56:1996;3173-3179.
4. Huebner K., Garrison P.N., Barnes L.D., Croce C.M. The role of the FHIT/FRA3B locus in cancer. Annu. Rev. Genet. 32:1998;7-31.
5. Sozzi G., Veronese M.L., Negrini M.et al. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell. 85:1996;17-26.
6. Virgilio L., Shuster M., Gollin S.M.et al. FHIT gene alterations in head and neck squamous cell carcinomas. Proc. Natl. Acad. Sci. USA. 93:1996;9770-9775.
7. Greenspan D.L., Connolly D.C., Wu R.et al. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res. 57:1997;4692-4698.
8. Simon B., Bartsch D., Barth P.et al. Frequent abnormalities of the putative tumor suppressor gene FHIT at 3p14.2 in pancreatic carcinoma cell lines. Cancer Res. 58:1998;1583-1587.
9. Sozzi G., Sard L., De Gregorio L.et al. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res. 57:1997;2121-2123.
10. Siprashvili Z., Sozzi G., Barnes L.D.et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc. Natl. Acad. Sci. USA. 94:1997;13771-13776.
11. Campiglio M., Pekarsky Y., Menard S., Tagliabue E., Pilotti S., Croce C.M. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res. 59:1999;3866-3869.
12. Sozzi G., Pastorino U., Moiraghi L.et al. Loss of FHIT function in lung cancer and pre-invasive bronchial lesions. Cancer Res. 58:1998;5032-5037.
13. Hadaczek P., Siprashvili Z., Markiewski M.et al. Absence or reduction of Fhit expression in most clear cell renal carcinomas. Cancer Res. 58:1998;2946-2951.
14. Ahmadian M., Wistuba I.I., Fong K.M.et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 57:1997;3664-3668.
15. Man S., Ellis I.O., Sibbering M., Blarney R.W., Brook J.D. High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. Cancer Res. 56:1996;5484-5489.
16. Ingvarsson S., Agnarsson B.A., Sigbjornsdottir B.I.et al. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas. Cancer Res. 59:1999;2682-2689.
17. Hayashi S., Tanimoto K., Hajiro-Nakanishi K.et al. Abnormal FHIT transcripts in human breast carcinomas. a clinicopathological and epidemiological analysis of 61 Japanese cases Cancer Res. 57:1997;1981-1985.
18. Bieche I., Latil A., Becette V., Lidereau R. Study of FHIT transcripts in normal and malignant breast tissue. Genes Chrom. Cancer. 23:1998;292-299.
19. Eiriksdottir G., Bergthorsson J.T., Sigurdsson H.et al. Mapping of chromosome 3 alterations in human breast cancer using microsatellite PCR markers. correlation with clinical variables Int. J. Oncol. 6:1995;369-379.
20. Huiping C., Sigurgeirsdottir J.R., Jonasson J.G.et al. Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer. Br. J. Cancer. 81:1999;1103-1110.
21. Johannesdottir G., Gudmundsson J., Bergthorsson J.T.et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res. 56:1996;3663-3665.
22. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl. Acids Res. 16:1988;1215.
23. Smith S.A., Easton D.F., Evans D.G., Ponder B.A. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat. Genet. 2:1992;128-131.